Ligand Pharmaceuticals (NASDAQ:LGND) Reaches New 1-Year High – Still a Buy?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) shares reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $215.01 and last traded at $210.6450, with a volume of 79692 shares traded. The stock had previously closed at $208.16.

Key Headlines Impacting Ligand Pharmaceuticals

Here are the key news stories impacting Ligand Pharmaceuticals this week:

• Positive Sentiment: BofA starts coverage with a Buy and $244 price target (~10.3% upside vs. current price), calling Ligand a low‑risk way to access biopharma growth via a large royalty portfolio and high margins. B of A Securities initiates coverage of Ligand Pharmaceuticals (LGND) with buy recommendation
• Positive Sentiment: Market commentary and coverage note the same BofA initiation — framing Ligand’s royalty model as high‑margin, diversified, and supportive of sustained earnings growth. Ligand gains new Buy from BofA on high-margin, less risky narrative
• Positive Sentiment: Benzinga and other outlets report BofA’s initiation and $244 target, emphasizing the royalty portfolio (100+ assets) and the company’s role as a capital/tech partner that earns royalties rather than bearing full commercial risk. Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst
• Positive Sentiment: Proactive Investors highlights BofA’s view that Ligand’s royalty model and diversified asset base should drive continued high‑margin returns and earnings growth. Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says
• Positive Sentiment: American Banking News reports analysts’ average rating is “Moderate Buy,” reinforcing the positive consensus from recent initiations/coverage. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Rating of “Moderate Buy” by Analysts
• Positive Sentiment: Investor’s Business Daily flagged LGND as a “stock of the day” and noted a breakout, which can attract momentum and technical buyers alongside the analyst attention. IBD stock of the day: Ligand Pharma, biotech’s royalty arm, breaks out

Analysts Set New Price Targets

A number of equities analysts have recently commented on LGND shares. Stifel Nicolaus raised their target price on shares of Ligand Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Wednesday, December 10th. Citigroup initiated coverage on Ligand Pharmaceuticals in a report on Tuesday, December 9th. They issued a “buy” rating and a $270.00 price target for the company. Bank of America began coverage on Ligand Pharmaceuticals in a research report on Wednesday. They issued a “buy” rating and a $244.00 price objective on the stock. HC Wainwright boosted their price objective on Ligand Pharmaceuticals from $231.00 to $239.00 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. Finally, Wall Street Zen downgraded Ligand Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $245.00.

Ligand Pharmaceuticals Price Performance

The company has a current ratio of 22.23, a quick ratio of 21.98 and a debt-to-equity ratio of 0.44. The stock has a market cap of $4.41 billion, a PE ratio of 37.95 and a beta of 1.17. The company’s 50 day moving average is $195.57 and its 200-day moving average is $188.57.

Ligand Pharmaceuticals (NASDAQ:LGND) last posted its quarterly earnings data on Thursday, February 26th. The biotechnology company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.56. The company had revenue of $59.67 million during the quarter, compared to analysts’ expectations of $55.59 million. Ligand Pharmaceuticals had a net margin of 46.42% and a return on equity of 13.86%. The firm’s revenue for the quarter was up 39.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.27 EPS. Ligand Pharmaceuticals has set its FY 2026 guidance at 8.000-9.000 EPS. As a group, sell-side analysts predict that Ligand Pharmaceuticals Incorporated will post 1.73 earnings per share for the current year.

Insiders Place Their Bets

In other Ligand Pharmaceuticals news, CFO Octavio Espinoza sold 13,423 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $205.83, for a total value of $2,762,856.09. Following the transaction, the chief financial officer directly owned 21,662 shares of the company’s stock, valued at $4,458,689.46. This represents a 38.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director John W. Kozarich sold 467 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $200.50, for a total value of $93,633.50. Following the transaction, the director owned 42,720 shares of the company’s stock, valued at approximately $8,565,360. This trade represents a 1.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 23,662 shares of company stock worth $4,817,826. Company insiders own 7.00% of the company’s stock.

Institutional Trading of Ligand Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Salomon & Ludwin LLC bought a new position in Ligand Pharmaceuticals during the 3rd quarter valued at $26,000. CIBC Private Wealth Group LLC increased its position in shares of Ligand Pharmaceuticals by 86.3% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 149 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 69 shares during the last quarter. Kestra Advisory Services LLC bought a new stake in shares of Ligand Pharmaceuticals in the 4th quarter worth about $31,000. Richardson Financial Services Inc. raised its stake in shares of Ligand Pharmaceuticals by 85.8% in the 3rd quarter. Richardson Financial Services Inc. now owns 210 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 97 shares in the last quarter. Finally, USA Financial Formulas bought a new position in shares of Ligand Pharmaceuticals during the fourth quarter worth about $43,000. Institutional investors own 91.28% of the company’s stock.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.